Reperfusion Treatment in Acute Pulmonary Embolism

Launched by SAHLGRENSKA UNIVERSITY HOSPITAL · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying different ways to treat patients who have a serious condition called acute pulmonary embolism (PE), which occurs when a blood clot blocks blood flow in the lungs. The trial is comparing two main treatments: systemic thrombolysis (ST), a method that uses medication to dissolve the clot quickly, and catheter-directed intervention (CDI), a less common procedure that delivers treatment directly to the clot. While ST is the standard treatment for high-risk patients, it can sometimes cause severe bleeding. CDI is being explored as an alternative for patients who cannot receive ST or do not improve with other treatments.

To participate in this trial, you must be an adult (18 years or older) with a confirmed diagnosis of acute pulmonary embolism. This includes pregnant women, and if a patient cannot give consent, a waiver will be used. Participants will receive either ST or CDI based on their specific condition. The trial is currently looking for volunteers, and anyone interested should speak with their healthcare provider to see if they qualify. It's important to know that while this trial is exploring new treatment options, the use of CDI is becoming more common even in cases that don’t meet the strict treatment criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All adult patients (≥18 years), including pregnant women, with verified (CTPA, angiography or scintigraphy) acute pulmonary embolism who are planned for, or have received, treatment with catheter directed intervention or systemic thrombolysis
• • Informed consent (for patients who do not survive before informed consent can be obtained, a waiver of consent applies)
• Exclusion Criteria:
• • Ongoing enrolment in interventional catheter directed intervention trial
• • Surgical embolectomy as primary reperfusion treatment